Category: BioTech

BioTech, Finance

Biotech Stock News: Biogen’s Q2 Earnings leads to a Stock Rise

Biogen Idec (BIIB) reported second quarter 2014 earnings per share of $3.48 (including the impact of stock-based compensation expense), way above the Consensus Estimate of $2.80 and the year-ago earnings of $2.29 per share. While oral multiple sclerosis (MS) drug, Tecfidera contributed significantly to revenues, the company also benefited from the approval of an agreement with the Italian National Medicines Agency (AIFA) relating to Tysabri … Continue reading Biotech Stock News: Biogen’s Q2 Earnings leads to a Stock Rise

Richard Atkins
Analysis, BioTech, Finance

Active Biotech Stock: Alkermes’ Pipeline Development Impresses, Stock Rises Up

Alkermes (NASDAQ ALKS) is leaving no stone unturned to develop its pipeline successfully. The biopharmaceutical company’s pipeline expanded significantly following the purchase of the erstwhile Elan’s drug delivery unit. Elan was acquired by Perrigo Company (NASDAQ PRGO) last year. Important pipeline candidates at Alkermes include ALKS 5461 for treating patients suffering from major depressive disorder (phase III), aripiprazole lauroxil (phase III), ALKS 3831 (phase II) … Continue reading Active Biotech Stock: Alkermes’ Pipeline Development Impresses, Stock Rises Up

Richard Atkins
BioTech, Finance

Top Biotech Stock: Amgen’s AMG 416 Succeeds in Phase III

Amgen Inc(AMGN) shares were up 2.5% following the company’s announcement that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a randomized, double-blind, placebo-controlled 26-week long phase III study. The study evaluated the efficacy and safety of AMG 416 in 515 chronic kidney disease (CKD) patients receiving hemodialysis and suffering from secondary hyperparathyroidism. Results showed that patients on … Continue reading Top Biotech Stock: Amgen’s AMG 416 Succeeds in Phase III

Richard Atkins
FB Nasdaq FB Facebook
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

DoCoMo Reports In-Line Fiscal 4Q, but Provides Lower Guidance; Under Review

NTT DoCoMo DCM reported fiscal year-end results that were generally in line with our expectations, but margin guidance for this year was lower than we anticipated. We have put our fair value estimate under review as we revise our model projections. There is no change to our economic moat rating. Revenue grew 5.4% year over year, a bit below our projection of 6.5%. DoCoMo increased … Continue reading DoCoMo Reports In-Line Fiscal 4Q, but Provides Lower Guidance; Under Review

John MeadyLeave a comment
BioTech, Finance

Biotech Stock To Buy: InterMune(ITMN) Gets Breakthrough Therapy Designation

InterMune, Inc. (ITMN ) received breakthrough therapy designation for its primary product, Esbriet (pirfenidone), from the FDA. InterMune is looking to get Esbriet approved in the U.S. for the treatment of adults suffering from idiopathic pulmonary fibrosis (IPF). Breakthrough therapy designation is a status provided to candidates that show superiority over existing therapies for the treatment of serious or life threatening diseases or conditions. The … Continue reading Biotech Stock To Buy: InterMune(ITMN) Gets Breakthrough Therapy Designation

Richard Atkins
PRAN NASDAQ PRAN Prana Biotechnology
BioTech, Finance

Active Biotech Stock: AbbVie Set to Acquire UK-Based Shire in Q4

AbbVie Inc and Shire have finally reached an agreement regarding the proposed acquisition of the latter by the former. As per the terms of the merger, AbbVie will pay approximately £53.19 per Shire share (£24.44 in cash and 0.8960 ordinary shares of the merged company for each Shire share). The deal is valued at £31.83 billion or approximately $54.5 billion. The agreed takeover price of … Continue reading Active Biotech Stock: AbbVie Set to Acquire UK-Based Shire in Q4

Richard Atkins